Clinical Trial Monitoring
Tozorakimab misses efficacy endpoint in Phase IIb for DKD
AstraZeneca progressed tozorakimab, a monoclonal antibody that acts by targeting interleukin-33, into Phase IIb trials for DKD in 2019.
AstraZeneca progressed tozorakimab, a monoclonal antibody that acts by targeting interleukin-33, into Phase IIb trials for DKD in 2019.